Skip to main content
OpenTrials
Completed

NCT Number: NCT03122366

TLR4 Polymorphisms and Risk of Skin Cancer

Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene. Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Kirklin Clinic

Birmingham, Alabama, 35294, United States

About this study

Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptors generally, and TLR4 in particular, appear to play a role in cancer susceptibility as well as tumor immunosuppression and stromal invasion. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene, and which was later shown to co-segregate with SNP Thr399Ile-also in the third exon of TLR4.1 This SNP, present in 10% of the general population, has been found associated with gastric cancer, prostate cancer, and nasopharyngeal cancer.2-4 Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female over the age of 50
  • Fitzpatrick skin type I-IV

Exclusion criteria

  • Tumor types other than basal cell carcinoma, squamous cell carcinoma and melanoma
  • Chronic immunosuppression due to transplant antirejection regimen or HIV/AIDS
  • Nevoid basal cell carcinoma syndrome, Cowden's syndrome, xeroderma pigmentosum or other syndrome with skin-cancer predisposition
  • Known exposure to arsenic or ionizing radiation

Treatment and study plan

Detection of single nucleotide polymorphisms (SNP)

Diagnostic Test

Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood

Primary outcomes

  1. single nucleotide polymorphism

    Time frame: once during the course of study

    TLR4 SNP Asp299Gly

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Registry information

Official study title

TLR4 Polymorphisms and Predisposition for Skin Cancer Development

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Apr 20, 2017
Registry last updated
Mar 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.